| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 18 | 2018 | 280 | 3.220 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 13 | 2018 | 54 | 3.160 |
Why?
|
| Infant, Premature | 28 | 2019 | 299 | 1.920 |
Why?
|
| Bronchopulmonary Dysplasia | 11 | 2018 | 43 | 1.770 |
Why?
|
| Infant, Newborn | 52 | 2023 | 2499 | 1.600 |
Why?
|
| Infant, Very Low Birth Weight | 7 | 2017 | 52 | 0.900 |
Why?
|
| Developmental Disabilities | 7 | 2018 | 203 | 0.900 |
Why?
|
| Intensive Care, Neonatal | 7 | 2019 | 13 | 0.900 |
Why?
|
| Persistent Fetal Circulation Syndrome | 5 | 2018 | 7 | 0.870 |
Why?
|
| Infant, Premature, Diseases | 7 | 2012 | 77 | 0.860 |
Why?
|
| Administration, Inhalation | 16 | 2018 | 192 | 0.850 |
Why?
|
| Bronchodilator Agents | 4 | 2012 | 66 | 0.770 |
Why?
|
| Vasodilator Agents | 3 | 2010 | 145 | 0.760 |
Why?
|
| Parents | 8 | 2012 | 290 | 0.730 |
Why?
|
| Child Development | 4 | 2012 | 169 | 0.690 |
Why?
|
| Hemodynamics | 12 | 2012 | 738 | 0.670 |
Why?
|
| Respiration, Artificial | 13 | 2018 | 358 | 0.660 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 21 | 0.640 |
Why?
|
| Asphyxia Neonatorum | 1 | 2018 | 7 | 0.630 |
Why?
|
| Catheterization, Peripheral | 1 | 2019 | 60 | 0.620 |
Why?
|
| Cerebral Palsy | 8 | 2022 | 97 | 0.620 |
Why?
|
| Gestational Age | 10 | 2019 | 329 | 0.600 |
Why?
|
| Noninvasive Ventilation | 1 | 2017 | 24 | 0.570 |
Why?
|
| Ethics, Medical | 6 | 2010 | 306 | 0.500 |
Why?
|
| Neuroprotective Agents | 2 | 2022 | 100 | 0.490 |
Why?
|
| Nitroprusside | 2 | 2003 | 32 | 0.440 |
Why?
|
| Decision Making | 8 | 2012 | 670 | 0.430 |
Why?
|
| Premature Birth | 2 | 2018 | 120 | 0.430 |
Why?
|
| Infant, Extremely Premature | 3 | 2018 | 30 | 0.420 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2012 | 77 | 0.410 |
Why?
|
| Erythropoietin | 2 | 2023 | 90 | 0.410 |
Why?
|
| Hypoxia-Ischemia, Brain | 2 | 2023 | 52 | 0.400 |
Why?
|
| Hypothermia, Induced | 2 | 2023 | 82 | 0.400 |
Why?
|
| Infant, Extremely Low Birth Weight | 2 | 2011 | 26 | 0.390 |
Why?
|
| Cocaine | 5 | 1995 | 77 | 0.390 |
Why?
|
| Informed Consent | 3 | 2012 | 275 | 0.390 |
Why?
|
| Intensive Care Units, Neonatal | 6 | 2019 | 73 | 0.390 |
Why?
|
| Medical Futility | 2 | 2010 | 31 | 0.390 |
Why?
|
| SRS-A | 6 | 1992 | 27 | 0.380 |
Why?
|
| Humans | 62 | 2023 | 89968 | 0.360 |
Why?
|
| Right to Die | 1 | 2010 | 12 | 0.360 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2010 | 6 | 0.360 |
Why?
|
| Counseling | 1 | 2012 | 166 | 0.350 |
Why?
|
| Professional-Family Relations | 2 | 2010 | 54 | 0.350 |
Why?
|
| Truth Disclosure | 2 | 2010 | 93 | 0.350 |
Why?
|
| Craniocerebral Trauma | 1 | 2010 | 56 | 0.340 |
Why?
|
| Scalp | 1 | 2010 | 72 | 0.340 |
Why?
|
| Reading | 1 | 2009 | 31 | 0.340 |
Why?
|
| Vascular Resistance | 3 | 2008 | 105 | 0.340 |
Why?
|
| Pulmonary Circulation | 7 | 2002 | 90 | 0.330 |
Why?
|
| Central Nervous System Diseases | 1 | 2008 | 52 | 0.310 |
Why?
|
| Hypertension, Pulmonary | 8 | 2002 | 366 | 0.310 |
Why?
|
| Hypoxia | 8 | 2013 | 657 | 0.310 |
Why?
|
| Female | 38 | 2022 | 46594 | 0.310 |
Why?
|
| Streptococcus agalactiae | 3 | 1993 | 11 | 0.310 |
Why?
|
| Empathy | 1 | 2010 | 151 | 0.310 |
Why?
|
| Hemorrhage | 1 | 2010 | 287 | 0.300 |
Why?
|
| Sheep | 17 | 1996 | 251 | 0.300 |
Why?
|
| Male | 30 | 2022 | 42680 | 0.290 |
Why?
|
| Morbidity | 1 | 2008 | 149 | 0.290 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2010 | 222 | 0.290 |
Why?
|
| Infant | 10 | 2023 | 3191 | 0.280 |
Why?
|
| Cause of Death | 1 | 2008 | 269 | 0.280 |
Why?
|
| Respiratory Insufficiency | 3 | 2010 | 162 | 0.270 |
Why?
|
| Movement | 3 | 2022 | 313 | 0.270 |
Why?
|
| Neuropsychological Tests | 5 | 2018 | 508 | 0.260 |
Why?
|
| Infant, Low Birth Weight | 5 | 2019 | 58 | 0.260 |
Why?
|
| Animals, Newborn | 11 | 2002 | 524 | 0.260 |
Why?
|
| Physician-Patient Relations | 2 | 2010 | 624 | 0.250 |
Why?
|
| Child, Preschool | 8 | 2018 | 3773 | 0.250 |
Why?
|
| White Matter | 2 | 2016 | 85 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 3680 | 0.240 |
Why?
|
| Cerebral Arteries | 2 | 1995 | 75 | 0.240 |
Why?
|
| Dissent and Disputes | 3 | 2005 | 29 | 0.230 |
Why?
|
| Treatment Outcome | 9 | 2018 | 8273 | 0.220 |
Why?
|
| Heart Rate | 4 | 2003 | 498 | 0.220 |
Why?
|
| Leukomalacia, Periventricular | 4 | 2009 | 18 | 0.210 |
Why?
|
| Vasoconstriction | 3 | 1995 | 92 | 0.210 |
Why?
|
| Research Design | 1 | 2006 | 591 | 0.210 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 983 | 0.200 |
Why?
|
| Treatment Refusal | 2 | 2007 | 62 | 0.200 |
Why?
|
| Birth Weight | 5 | 2013 | 148 | 0.200 |
Why?
|
| Pregnancy | 11 | 2022 | 3048 | 0.190 |
Why?
|
| Language Development Disorders | 2 | 2018 | 24 | 0.190 |
Why?
|
| Personal Autonomy | 2 | 2006 | 115 | 0.190 |
Why?
|
| Predictive Value of Tests | 5 | 2022 | 1732 | 0.190 |
Why?
|
| Prospective Studies | 11 | 2018 | 4331 | 0.180 |
Why?
|
| Infant Mortality | 2 | 2017 | 59 | 0.180 |
Why?
|
| Child | 5 | 2018 | 7244 | 0.180 |
Why?
|
| Refusal to Treat | 3 | 1999 | 27 | 0.170 |
Why?
|
| Group Processes | 2 | 1996 | 31 | 0.170 |
Why?
|
| Nervous System | 2 | 2012 | 91 | 0.170 |
Why?
|
| Retinopathy of Prematurity | 2 | 2019 | 73 | 0.160 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 23 | 0.160 |
Why?
|
| Cerebrovascular Circulation | 3 | 1996 | 232 | 0.160 |
Why?
|
| Laser Coagulation | 1 | 2019 | 55 | 0.160 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 117 | 0.150 |
Why?
|
| Resuscitation Orders | 3 | 2005 | 65 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 3 | 2012 | 341 | 0.150 |
Why?
|
| Risk Factors | 6 | 2011 | 5559 | 0.150 |
Why?
|
| Motor Disorders | 1 | 2018 | 7 | 0.150 |
Why?
|
| Japan | 1 | 2018 | 304 | 0.150 |
Why?
|
| Bevacizumab | 1 | 2019 | 268 | 0.150 |
Why?
|
| Double-Blind Method | 3 | 2022 | 1714 | 0.150 |
Why?
|
| Device Removal | 1 | 2019 | 168 | 0.140 |
Why?
|
| Methylene Blue | 1 | 1996 | 18 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 293 | 0.140 |
Why?
|
| Fetus | 2 | 1995 | 232 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2019 | 785 | 0.140 |
Why?
|
| Medicine in Literature | 2 | 2006 | 8 | 0.130 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2016 | 47 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2018 | 234 | 0.130 |
Why?
|
| Streptococcal Infections | 2 | 1993 | 56 | 0.130 |
Why?
|
| Retrospective Studies | 6 | 2019 | 9210 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 155 | 0.130 |
Why?
|
| Chromones | 4 | 1991 | 31 | 0.130 |
Why?
|
| Withholding Treatment | 4 | 2007 | 116 | 0.120 |
Why?
|
| Biogenic Monoamines | 1 | 1995 | 9 | 0.120 |
Why?
|
| Echoencephalography | 2 | 2011 | 12 | 0.120 |
Why?
|
| Narcotics | 1 | 1995 | 71 | 0.120 |
Why?
|
| Terminal Care | 2 | 2006 | 137 | 0.120 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2018 | 60 | 0.110 |
Why?
|
| Registries | 1 | 2018 | 808 | 0.110 |
Why?
|
| Epinephrine | 2 | 1992 | 89 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2011 | 1929 | 0.110 |
Why?
|
| Oxygen | 4 | 2003 | 745 | 0.110 |
Why?
|
| Leukoencephalopathies | 1 | 2012 | 16 | 0.100 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2002 | 32 | 0.100 |
Why?
|
| Animals | 20 | 2002 | 27528 | 0.100 |
Why?
|
| Brain | 4 | 2016 | 2307 | 0.100 |
Why?
|
| Aminophylline | 1 | 1992 | 14 | 0.100 |
Why?
|
| Moral Obligations | 2 | 2007 | 53 | 0.100 |
Why?
|
| Indomethacin | 2 | 2008 | 59 | 0.100 |
Why?
|
| Lung | 3 | 2008 | 1292 | 0.100 |
Why?
|
| Norwood Procedures | 1 | 2012 | 40 | 0.100 |
Why?
|
| Alkalosis, Respiratory | 2 | 1988 | 4 | 0.100 |
Why?
|
| Resuscitation | 2 | 2007 | 111 | 0.100 |
Why?
|
| Oleic Acids | 1 | 1991 | 26 | 0.100 |
Why?
|
| Arachidonic Acid | 1 | 1991 | 63 | 0.100 |
Why?
|
| Intuition | 1 | 2011 | 8 | 0.090 |
Why?
|
| ROC Curve | 2 | 2013 | 778 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2013 | 493 | 0.090 |
Why?
|
| Incidence | 3 | 2005 | 1603 | 0.090 |
Why?
|
| Paternalism | 1 | 2010 | 24 | 0.090 |
Why?
|
| High-Frequency Ventilation | 1 | 2010 | 9 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2018 | 2887 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2008 | 2327 | 0.090 |
Why?
|
| Positive-Pressure Respiration | 1 | 2010 | 40 | 0.090 |
Why?
|
| Pregnancy in Diabetics | 1 | 2010 | 38 | 0.090 |
Why?
|
| Palliative Care | 1 | 2012 | 264 | 0.090 |
Why?
|
| Hydrops Fetalis | 1 | 1989 | 16 | 0.090 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 25 | 0.090 |
Why?
|
| Interleukin-8 | 2 | 2012 | 86 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 1682 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 296 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 163 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 221 | 0.080 |
Why?
|
| Delivery, Obstetric | 1 | 1989 | 120 | 0.080 |
Why?
|
| Ductus Arteriosus, Patent | 2 | 2008 | 40 | 0.080 |
Why?
|
| Social Class | 1 | 2009 | 137 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 865 | 0.080 |
Why?
|
| Age Factors | 2 | 2012 | 1880 | 0.080 |
Why?
|
| Catheterization | 2 | 1994 | 237 | 0.080 |
Why?
|
| Apgar Score | 1 | 2008 | 13 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 39 | 0.080 |
Why?
|
| Patient Participation | 1 | 2010 | 226 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2010 | 166 | 0.080 |
Why?
|
| Students | 1 | 2009 | 171 | 0.070 |
Why?
|
| Patient Care Team | 1 | 1989 | 284 | 0.070 |
Why?
|
| Probability | 1 | 2008 | 351 | 0.070 |
Why?
|
| Persistent Vegetative State | 1 | 2007 | 9 | 0.070 |
Why?
|
| Inflammation | 1 | 2012 | 981 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 596 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2003 | 1862 | 0.070 |
Why?
|
| Social Values | 2 | 1996 | 44 | 0.070 |
Why?
|
| Life Support Care | 1 | 2007 | 50 | 0.070 |
Why?
|
| Hyperventilation | 1 | 1986 | 13 | 0.070 |
Why?
|
| Lung Diseases | 2 | 2010 | 275 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 1083 | 0.070 |
Why?
|
| Blood | 1 | 1986 | 69 | 0.060 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2005 | 10 | 0.060 |
Why?
|
| Heart | 1 | 2008 | 578 | 0.060 |
Why?
|
| Third-Party Consent | 1 | 2005 | 24 | 0.060 |
Why?
|
| Blindness | 1 | 2005 | 39 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2010 | 958 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2004 | 72 | 0.060 |
Why?
|
| Physicians | 1 | 2012 | 692 | 0.060 |
Why?
|
| Educational Status | 1 | 2005 | 195 | 0.060 |
Why?
|
| Advance Directive Adherence | 1 | 2004 | 6 | 0.060 |
Why?
|
| Umbilical Arteries | 1 | 1984 | 17 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2008 | 1498 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 682 | 0.060 |
Why?
|
| Linear Models | 1 | 2005 | 421 | 0.060 |
Why?
|
| Respiratory Mucosa | 1 | 2004 | 88 | 0.060 |
Why?
|
| Intellectual Disability | 1 | 2005 | 190 | 0.060 |
Why?
|
| Liability, Legal | 1 | 2004 | 32 | 0.060 |
Why?
|
| Respiratory Function Tests | 2 | 2002 | 140 | 0.060 |
Why?
|
| Unconsciousness | 1 | 2003 | 4 | 0.050 |
Why?
|
| Drowning | 1 | 2003 | 3 | 0.050 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2003 | 13 | 0.050 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 17 | 0.050 |
Why?
|
| Reference Values | 2 | 2002 | 662 | 0.050 |
Why?
|
| Oximetry | 1 | 2003 | 82 | 0.050 |
Why?
|
| Norepinephrine | 2 | 1995 | 172 | 0.050 |
Why?
|
| Intubation | 1 | 2003 | 21 | 0.050 |
Why?
|
| Cold Temperature | 1 | 2023 | 160 | 0.050 |
Why?
|
| Chloralose | 2 | 1992 | 6 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2022 | 9 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2003 | 130 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2022 | 56 | 0.050 |
Why?
|
| Random Allocation | 1 | 2002 | 327 | 0.050 |
Why?
|
| Uncertainty | 2 | 2007 | 76 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 305 | 0.050 |
Why?
|
| Pregnancy Complications | 2 | 1996 | 345 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2011 | 591 | 0.050 |
Why?
|
| United States | 5 | 2010 | 7108 | 0.050 |
Why?
|
| Texas | 3 | 2007 | 116 | 0.050 |
Why?
|
| Lung Injury | 2 | 2011 | 53 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2014 | 191 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2004 | 469 | 0.050 |
Why?
|
| Swine | 1 | 2002 | 590 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2002 | 899 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2002 | 872 | 0.040 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 2 | 1989 | 6 | 0.040 |
Why?
|
| Vision, Low | 1 | 2019 | 15 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2019 | 73 | 0.040 |
Why?
|
| Logistic Models | 1 | 2003 | 1214 | 0.040 |
Why?
|
| Hearing Loss | 1 | 2019 | 62 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 1704 | 0.040 |
Why?
|
| Social Skills | 1 | 2018 | 8 | 0.040 |
Why?
|
| Academic Success | 1 | 2018 | 11 | 0.040 |
Why?
|
| Intelligence Tests | 1 | 2018 | 38 | 0.040 |
Why?
|
| Respiratory Therapy | 1 | 2017 | 14 | 0.040 |
Why?
|
| Executive Function | 1 | 2018 | 93 | 0.040 |
Why?
|
| Labor, Induced | 1 | 1997 | 30 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 1996 | 137 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 841 | 0.030 |
Why?
|
| Virginia | 1 | 1996 | 16 | 0.030 |
Why?
|
| Anencephaly | 1 | 1996 | 7 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1996 | 105 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1996 | 126 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1988 | 503 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 1996 | 28 | 0.030 |
Why?
|
| Shock, Septic | 1 | 1996 | 105 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 700 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2017 | 357 | 0.030 |
Why?
|
| Cardiac Output | 2 | 1993 | 155 | 0.030 |
Why?
|
| Adult | 4 | 2010 | 26822 | 0.030 |
Why?
|
| Potassium Chloride | 1 | 1995 | 86 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 2 | 1986 | 111 | 0.030 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 1994 | 7 | 0.030 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 1994 | 4 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1994 | 32 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 151 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 749 | 0.030 |
Why?
|
| Diuresis | 1 | 2013 | 26 | 0.030 |
Why?
|
| Calibration | 1 | 2013 | 103 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2013 | 50 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1899 | 0.030 |
Why?
|
| Serotonin | 1 | 1995 | 221 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 126 | 0.030 |
Why?
|
| Bias | 1 | 2013 | 135 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 338 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 996 | 0.030 |
Why?
|
| Serum Amyloid A Protein | 1 | 2012 | 25 | 0.030 |
Why?
|
| Patient Selection | 1 | 1996 | 682 | 0.030 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 1989 | 7 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2012 | 85 | 0.030 |
Why?
|
| Receptors, Leukotriene | 1 | 1992 | 10 | 0.030 |
Why?
|
| Hydroxyquinolines | 1 | 1992 | 4 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1992 | 105 | 0.020 |
Why?
|
| Acetophenones | 1 | 1992 | 27 | 0.020 |
Why?
|
| Tetrazoles | 1 | 1992 | 24 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 233 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1992 | 238 | 0.020 |
Why?
|
| Oleic Acid | 1 | 1991 | 15 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 192 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1993 | 160 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1992 | 136 | 0.020 |
Why?
|
| Species Specificity | 1 | 1993 | 685 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2011 | 120 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2010 | 38 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 60 | 0.020 |
Why?
|
| Blood Pressure | 3 | 1989 | 906 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2018 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 657 | 0.020 |
Why?
|
| Injections | 1 | 1990 | 116 | 0.020 |
Why?
|
| Thromboxane A2 | 1 | 1989 | 10 | 0.020 |
Why?
|
| Tibia | 1 | 1990 | 78 | 0.020 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1989 | 34 | 0.020 |
Why?
|
| Epoprostenol | 1 | 1989 | 46 | 0.020 |
Why?
|
| Prenatal Care | 1 | 1989 | 77 | 0.020 |
Why?
|
| Femur | 1 | 1990 | 112 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 1989 | 110 | 0.020 |
Why?
|
| Cromolyn Sodium | 1 | 1988 | 3 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 1990 | 114 | 0.020 |
Why?
|
| Mast Cells | 1 | 1988 | 94 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1993 | 420 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 98 | 0.020 |
Why?
|
| Neonatology | 1 | 2007 | 11 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2007 | 32 | 0.020 |
Why?
|
| Parental Consent | 1 | 2007 | 35 | 0.020 |
Why?
|
| Urination | 1 | 1986 | 38 | 0.020 |
Why?
|
| Famous Persons | 1 | 2006 | 8 | 0.020 |
Why?
|
| Alkalosis | 1 | 1986 | 10 | 0.020 |
Why?
|
| History, 19th Century | 1 | 2006 | 56 | 0.020 |
Why?
|
| Freedom | 1 | 2006 | 18 | 0.020 |
Why?
|
| Negotiating | 1 | 2006 | 20 | 0.020 |
Why?
|
| Ethics, Clinical | 1 | 2006 | 48 | 0.020 |
Why?
|
| Transducers | 2 | 1996 | 42 | 0.020 |
Why?
|
| Dopamine | 1 | 1986 | 276 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1986 | 201 | 0.020 |
Why?
|
| Arteries | 1 | 1986 | 179 | 0.020 |
Why?
|
| Suction | 1 | 2004 | 37 | 0.010 |
Why?
|
| Endotoxins | 1 | 2004 | 36 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 65 | 0.010 |
Why?
|
| Wrongful Life | 1 | 2004 | 1 | 0.010 |
Why?
|
| Choice Behavior | 1 | 2006 | 160 | 0.010 |
Why?
|
| Jurisprudence | 1 | 2004 | 25 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 2458 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 1984 | 114 | 0.010 |
Why?
|
| Trachea | 1 | 2004 | 292 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 3798 | 0.010 |
Why?
|
| Echocardiography | 1 | 2008 | 944 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1913 | 0.010 |
Why?
|
| Ultrasonography | 2 | 1996 | 720 | 0.010 |
Why?
|
| Hospitals | 1 | 2004 | 303 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 961 | 0.010 |
Why?
|
| Anesthesia | 2 | 1994 | 169 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2004 | 689 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1158 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1054 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2887 | 0.010 |
Why?
|
| Methemoglobinemia | 1 | 1997 | 10 | 0.010 |
Why?
|
| Intention | 1 | 1997 | 51 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1996 | 72 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 198 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 1996 | 63 | 0.010 |
Why?
|
| Amniotic Fluid | 1 | 1994 | 30 | 0.010 |
Why?
|
| Ultrasonics | 1 | 1994 | 39 | 0.010 |
Why?
|
| Consciousness | 1 | 1994 | 28 | 0.010 |
Why?
|
| Abortion, Induced | 1 | 1997 | 139 | 0.010 |
Why?
|
| Respiration | 1 | 1996 | 267 | 0.010 |
Why?
|
| Life Support Systems | 1 | 1993 | 2 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1994 | 109 | 0.010 |
Why?
|
| Abruptio Placentae | 1 | 1993 | 13 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1992 | 62 | 0.010 |
Why?
|
| Ventricular Function | 1 | 1992 | 53 | 0.010 |
Why?
|
| Uterus | 1 | 1994 | 222 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1992 | 103 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1992 | 245 | 0.010 |
Why?
|
| Seizures | 1 | 1993 | 308 | 0.010 |
Why?
|
| Models, Biological | 1 | 1995 | 1765 | 0.000 |
Why?
|
| Hypertension | 1 | 1994 | 747 | 0.000 |
Why?
|
| Time Factors | 1 | 1997 | 5359 | 0.000 |
Why?
|